Read More 1 minute read Analyst Ratings News Price Target Reiteration Susquehanna Reiterates Neutral on Coherent, Maintains $45 Price Target By Benzinga Newsdesk Today, 8:38 AM Susquehanna analyst Mehdi Hosseini reiterates Coherent (NYSE:COHR) with a Neutral and maintains $45 price target. COHR
Read More 1 minute read Analyst Ratings News Price Target Reiteration Stephens & Co. Reiterates Overweight on Noodles, Maintains $7 Price Target By Benzinga Newsdesk Today, 8:38 AM Stephens & Co. analyst Joshua Long reiterates Noodles (NASDAQ:NDLS) with a Overweight and maintains $7 price target. NDLS
Read More 1 minute read Analyst Ratings News Price Target Reiteration Cantor Fitzgerald Reiterates Overweight on Jasper Therapeutics, Maintains $6 Price Target By Benzinga Newsdesk Today, 8:38 AM Cantor Fitzgerald analyst Pete Stavropoulos reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Overweight and maintains $6 price target. JSPR
Read More 1 minute read Analyst Ratings News Price Target Reiteration Benchmark Reiterates Buy on Ideal Power, Maintains $18 Price Target By Benzinga Newsdesk Today, 8:38 AM Benchmark analyst David Williams reiterates Ideal Power (NASDAQ:IPWR) with a Buy and maintains $18 price target. IPWR
Read More 1 minute read Analyst Ratings News Price Target Reiteration Benchmark Reiterates Buy on Noodles, Maintains $10 Price Target By Benzinga Newsdesk Today, 8:38 AM Benchmark analyst Todd Brooks reiterates Noodles (NASDAQ:NDLS) with a Buy and maintains $10 price target. NDLS
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Mirum Pharmaceuticals, Maintains $61 Price Target By Benzinga Newsdesk Today, 8:38 AM HC Wainwright & Co. analyst Ed Arce reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and maintains $61 price target. MIRM
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on First Wave BioPharma, Maintains $18 Price Target By Benzinga Newsdesk Today, 8:38 AM HC Wainwright & Co. analyst Yi Chen reiterates First Wave BioPharma (NASDAQ:FWBI) with a Buy and maintains $18 price target. FWBI
Read More 1 minute read Analyst Ratings News Price Target Reiteration RBC Capital Reiterates Outperform on Nuvei, Maintains $50 Price Target By Benzinga Newsdesk Today, 8:38 AM RBC Capital analyst Paul Treiber reiterates Nuvei (NASDAQ:NVEI) with a Outperform and maintains $50 price target. NVEI
Read More 1 minute read Analyst Ratings News Price Target Reiteration RBC Capital Reiterates Outperform on Parex Resources, Maintains C$28 Price Target By Benzinga Newsdesk Today, 8:38 AM RBC Capital analyst Luke Davis reiterates Parex Resources (TSX:PXT) with a Outperform and maintains C$28 price target. TSX:PXT
Read More 1 minute read Analyst Ratings News Price Target Reiteration RBC Capital Reiterates Outperform on Kiwetinohk Energy, Maintains C$20 Price Target By Benzinga Newsdesk Today, 8:38 AM RBC Capital analyst Michael Harvey reiterates Kiwetinohk Energy (TSX:KEC) with a Outperform and maintains C$20 price target. TSX:KEC